Spyre Therapeutics, Inc. (SYRE) Shareholders’ equity 2016–2025
Spyre Therapeutics, Inc. (SYRE) shareholders’ equity at each fiscal year-end, per SEC filings.
$715.2MFY2025 · since FY2016: $63.0M → $715.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $715.2M | +38.1% |
| FY2024 | $517.8M | +181.4% |
| FY2023 | $184.0M | +265.8% |
| FY2022 | $50.3M | -40.1% |
| FY2021 | $83.9M | -40.0% |
| FY2020 | $139.8M | +132.7% |
| FY2019 | $60.1M | -10.9% |
| FY2018 | $67.4M | +34.0% |
| FY2017 | $50.3M | -20.1% |
| FY2016 | $63.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice